{
  "docId": "019de072-1970-7036-9d15-9ffed6304914",
  "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 35,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Clinical trial data showing hazard ratios and median survival times for secondary endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/16",
  "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914",
  "deckJsonHref": "/decks/019de072-1970-7036-9d15-9ffed6304914.json",
  "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.03,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Time to first subsequent therapy or death (TFST)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f09cd26-e7a6-46a2-803d-183f3a0cf11d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Time to second progression or death (PFS2)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d48885cc-ef8a-4f90-aa40-ff4b1de98524",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.15,
        "y": 0.5
      },
      "kind": "table",
      "text": "Summary statistics for TFST and PFS2 including HR, P-values, and median months.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "039bec5b-4ad5-4bfa-a3c9-182754106394",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "TFST and PFS2 results support longer-term benefit with olaparib + abiraterone",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4716fb9-154f-4383-b783-a872c08a1668",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Secondary endpoints: TFST and PFS2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4526757e-616e-4a6b-b0cc-c4849b844ad3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}